| 词条 | Rabbit hybridoma |
| 释义 |
A rabbit hybridoma is a hybrid cell line formed by the fusion of an antibody producing rabbit B cell with a cancerous B-cell (myeloma). HistoryThe rabbit immune system has been documented as a vehicle for developing antibodies with higher affinity and more diverse recognition of many molecules including phospho-peptides, carbohydrates and immunogens that are not otherwise immunogenic in mouse.[1] However, until recently, the type of antibodies available from rabbit had been limited in scope to polyclonal antibodies. Several efforts were made to generate rabbit monoclonal antibodies after the development of mouse hybridoma technology in the 1970s.[2] Research was conducted into mouse-rabbit hetero-hybridomas to make rabbit monoclonal antibodies.[1][3] However, these hetero-hybridomas were ultimately difficult to clone, and the clones, generally unstable, and did not secrete antibody over a prolonged period of time. Initial fusion partnerIn 1995, Katherine Knight and her colleagues, at Loyola University of Chicago, succeeded in developing a double transgenic rabbit over-expressing the oncogenes v-abl and c-myc under the control of the immunoglobulin heavy and light chain enhancers. The rabbit formed a myeloma-like tumor, allowing the isolation of a plasmacytoma cell line, named 240E-1. Fusion of 240E-1 cells with rabbit lymphocytes produced hybridomas that secreted rabbit monoclonal antibodies in a consistent manner.[4] However, like the early mouse myeloma lines developed in the 1970s, stability was a concern. A number of laboratories which had received the 240E-1 cell line from Dr. Knight’s laboratory reported stability problems with the fusion cell line 240E-1.[5] Improved fusion partnerIn 1996, Weimin Zhu and Robert Pytela, at the University of California San Francisco (UCSF), obtained 240E-1 from Dr. Knight’s laboratory and attempted to develop an improved rabbit hybridoma.[4] Improvements in the characteristics of 240E-1 were accomplished by repeated subcloning, selection for high fusion efficiency, robust growth, and morphological characteristics such as a bright appearance under a phase contrast microscope. Selected subclones were further tested for their ability to produce a stable hybridoma and monoclonal antibody secretion. After multiple rounds of subcloning and selection processes, a new cell line named 240E-W, was identified and which expressed better fusion efficiency and stability. Cell line 240E-W has since been further developed and optimized for production of rabbit monoclonal antibodies for research and commercial applications. ProcessThe process of hybridoma formation in a rabbit first entails obtaining B-cells from a rabbit that has been immunized. There are numerous immunization protocols for rabbit, notably for the generation of polyclonal antibodies.[6][7][8] After immunization, B-cells are fused with a candidate rabbit fusion partner cell line to form hybridomas. Resulting antibodies from hybridomas are screened for an antigen which meets criteria of interest by diagnostic tests such as ELISA, Western blot, Immunohistochemistry and FACS. The resulting hybrdomas may be subcloned to ensure monoclonal characteristics. Humanization of rabbit antibodiesMitchell Ho and colleagues at the National Cancer Institute isolated a number of rabbit monoclonal antibodies that recognize various rare epitopes of mesothelin, including poorly immunogenic regions, for cancer therapy. [9] Mitchell Ho and Yi-Fan Zhang analyzed the complex structures of rabbit antibodies with their antigens in the Protein Data Bank, and identified antigen-contacting residues on the rabbit Fv within the 6 Angstrom distance to its antigen.[10] They identified and named "HV4" and "LV4" in rabbit Fvs, non-complementarity-determining region (CDR) loops that are structurally close to the antigen and located in framework 3 of the rabbit heavy chain and light chain, respectively. Based on the structural analysis, they designed a humanization strategy by grafting the combined Kabat/IMGT/Paratome CDRs into a human germline framework sequence. Four immunotoxins composed of the humanized rabbit Fvs fused to a clinically used toxin showed stronger cytotoxicity against tumor cells than the immunotoxins derived from their original rabbit Fvs. The Ho-Zhang method (i.e. grafting combined Kabat/IMGT/Paratome CDRs to a stable human germline framework) may be a general approach to humanize rabbit antibodies.[10] References1. ^1 {{cite journal |pages=1788–90 |doi=10.1126/science.3289119 |title=Production of stable rabbit-mouse hybridomas that secrete rabbit mAb of defined specificity |year=1988 |last1=Raybould |first1=T. |last2=Takahashi |first2=M |journal=Science |volume=240 |issue=4860 |pmid=3289119|bibcode = 1988Sci...240.1788R }} 2. ^{{cite journal |jstor=62751 |pages=260–262 |last1=Collins |first1=J. J. |last2=Black |first2=P. H. |last3=Strosberg |first3=A. D. |last4=Haber |first4=E. |last5=Bloch |first5=K. J. |title=Transformation by Simian Virus 40 of Spleen Cells from a Hyperimmune Rabbit: Evidence for Synthesis of Immunoglobulin by the Transformed Cells |volume=71 |issue=2 |journal=Proceedings of the National Academy of Sciences of the United States of America |year=1974 |pmid=4150020 |pmc=387981 |doi=10.1073/pnas.71.2.260|bibcode = 1974PNAS...71..260C }} 3. ^{{cite journal |doi=10.1016/0161-5890(85)90119-1 |title=Rabbit-mouse hybridomas secreting intact rabbit immunoglobulin |year=1985 |last1=Mei-Chang |first1=Kuo |last2=Soon |first2=John A. |last3=Max |first3=Edward E. |last4=Kindt |first4=Thomas J. |journal=Molecular Immunology |volume=22 |issue=4 |pages=351–9 |pmid=4033662}} 4. ^1 {{cite journal |pmid=7568130 |year=1995 |last1=Spieker-Polet |first1=H |last2=Sethupathi |first2=P |last3=Yam |first3=PC |last4=Knight |first4=KL |title=Rabbit monoclonal antibodies: Generating a fusion partner to produce rabbit-rabbit hybridomas |volume=92 |issue=20 |pages=9348–52 |pmc=40982 |journal=Proceedings of the National Academy of Sciences of the United States of America |doi=10.1073/pnas.92.20.9348|bibcode = 1995PNAS...92.9348S }} 5. ^{{cite journal |pages=189–98 |doi=10.1089/027245701750293529 |title=Recombinant Human Interleukin-6 Enhances the Immunoglobulin Secretion of a Rabbit–Rabbit Hybridoma |year=2001 |last1=Liguori |first1=Michael J. |last2=Hoff-Velk |first2=Jane A. |last3=Ostrow |first3=David H. |journal=Hybridoma |volume=20 |issue=3 |pmid=11461668}} 6. ^Howard GC and Kaser MR, editors. Making and using antibodies: a practical handbook. CRC Press; 2007 7. ^Harlow E and Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory; 1988. 8. ^Coligan JE, Kruisbeek AM, et al. editors. Current protocols in immunology. Greene and Wiley; 1994. 9. ^{{Cite journal|last=Zhang|first=Yi-Fan|last2=Phung|first2=Yen|last3=Gao|first3=Wei|last4=Kawa|first4=Seiji|last5=Hassan|first5=Raffit|last6=Pastan|first6=Ira|last7=Ho|first7=Mitchell|date=2015-05-21|title=New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma|url=https://www.ncbi.nlm.nih.gov/pubmed/25996440|journal=Scientific Reports|volume=5|pages=9928|doi=10.1038/srep09928|issn=2045-2322|pmc=4440525|pmid=25996440}} Material was copied from this source, which is available under a [https://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International License]. 10. ^1 {{Cite journal|last=Zhang|first=Yi-Fan|last2=Ho|first2=Mitchell|date=April 2017|title=Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples|url=https://www.ncbi.nlm.nih.gov/pubmed/28165915|journal=mAbs|volume=9|issue=3|pages=419–429|doi=10.1080/19420862.2017.1289302|issn=1942-0870|pmc=5384799|pmid=28165915}} {{PD-notice}} External links
5 : Immunology|Biotechnology|Immune system|Monoclonal antibodies|Therapeutic antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。